Financial News
All News about Incyte Corp
![](/next-assets/images/schema-image-default.png)
Earnings Outlook For Incyte
February 06, 2023
Via Benzinga
![](https://g.foolcdn.com/editorial/images/718704/doctor-with-patient-talking.jpg)
![](/next-assets/images/schema-image-default.png)
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
January 31, 2023
Via Benzinga
![](https://mms.businesswire.com/media/20230124005025/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU2.jpg)
Golden Cross Appears Before Incyte Investors
December 09, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_28317.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
![](https://talkmarkets.com/images/logos/talkmarkets.png)
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers
January 18, 2023
Via Talk Markets
![](https://mms.businesswire.com/media/20230117005125/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
January 17, 2023
From Incyte
Via Business Wire
![](https://investorplace.com/wp-content/uploads/2019/08/healthcare1600c.jpg)
![](https://images.pexels.com/photos/2280549/pexels-photo-2280549.jpeg?auto=compress&cs=tinysrgb&h=750&w=1260)
Via Talk Markets
![](https://g.foolcdn.com/editorial/images/714268/pharmacist-talking-to-patient.jpg)
![](https://investorplace.com/wp-content/uploads/2022/07/healthcare-1600.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/12/16/stock-exchange-g894ab76ae_1920.jpg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20221215005007/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/12/13/screenshot_2022-12-13_at_4.40.52_pm.png?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20221211005037/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
December 11, 2022
From Incyte
Via Business Wire
![](https://mms.businesswire.com/media/20221210005030/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20221202005043/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20221117005001/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20221106005116/en/1627174/5/Mirati_Logo_Purple_JPG_File.jpg)
![](https://mms.businesswire.com/media/20221107005169/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://investorplace.com/wp-content/uploads/2022/10/stocks-to-buy-greedy1600-1024x576.png)
![](https://g.foolcdn.com/editorial/images/707345/doctor-with-patient-talking.jpg)
![](https://mms.businesswire.com/media/20221103005878/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_9182.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20221101005407/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
November 01, 2022
From Incyte
Via Business Wire
![](https://mms.businesswire.com/media/20221019006152/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.